James J. S. Treanor

TL;DR: Overexpression of a transmembrane aspartic protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta- secretase positions.

TL;DR: Results demonstrate that TRPV1‐selective antagonists like AMG 517 cannot be developed for systemic use as stand alone agents for treatment of pain and other diseases, individual susceptibility influences magnitude of hyperthermia observed after TRpV1 blockade, and TRPv1 plays a pivotal role as a molecular regulator for body temperature in humans.

TL;DR: Observations suggest that aberrant activity in uninjured C-fibers is a necessary component of pain associated with partial nerve injury and suggest that blocking NaV1.8 would be an effective treatment of neuropathic pain.

TL;DR: AMG 9810 is the first cinnamide TRPV1 antagonist reported to block capsaicin-induced eye wiping behavior and reverse hyperalgesia in an animal model of inflammatory pain.

TL;DR: Key residues (Met547 and Thr550) in transmembrane regions 3 and 4 of rat and human TRPV1 that confer vanilloid sensitivity, [3H]RTX binding and competitive antagonist binding to rabbit TRpV1 are identified and it is shown that these residues differentially affect ligand recognition as well as the assays of functional response versus ligand binding.